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Abstract
Background: Wiskott-Aldrich syndrome is a rare X-linked disorder characterized by microthrombocytopenia,
eczema, and recurrent infections. It is caused by mutations of the WAS gene. Microthrombocytopenia has been
regarded as the key criteria in diagnosing this rare condition. However, in this case report, we describe a case of
Wiskott-Aldrich syndrome with normal platelet size.
Case presentation: We report the case of a 9-month-old Malay boy who presented with persistent
thrombocytopenia from birth. Serial blood investigations at birth showed he had normal platelet size. His family
history revealed two early neonatal deaths in maternal uncles. Spontaneous bleeding was only seen at the age of
3 months. He was initially treated for immune thrombocytopenic purpura and was started on intravenously
administered immunoglobulin. His clinical deterioration and poor response to the immunoglobulin raised suspicion
for a different underlying pathology. Molecular analysis of the WAS gene revealed a missense mutation in exon 10.
His parents refused further interventions and defaulted on subsequent follow-up appointments.
Conclusions: A diagnosis of Wiskott-Aldrich syndrome should be considered in any male infant who presents with
early onset thrombocytopenia despite an absence of small platelet size, a characteristic feature of Wiskott-Aldrich
syndrome.
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Background
Wiskott-Aldrich syndrome (WAS) is a rare X-linked
disorder caused by a mutation in the Wiskott-Aldrich
syndrome gene (WAS) [1]. WAS affects 1–10 babies per
million male infants [2]. WAS mutations give rise to a
wide spectrum of phenotypes with differing severity. The
most severe form, referred to as classical WAS, is charac-
terized by a triad of thrombocytopenia, recurrent infec-
tions, and eczema, with an increased chance of developing
autoimmune conditions and malignancy. The milder form
of WAS, known as X-linked thrombocytopenia (XLT), is
characterized by thrombocytopenia with absent or mild
eczema/immunodeficiency [1, 2]. At present, hematopoietic
stem cell transplantation is the only curative therapy for
WAS [3]. Nevertheless, gene therapy has recently emerged
as a new form of treatment and shows promising results.
Further studies on its long-term outcomes and safety are
warranted [4].
The WAS gene encodes the Wiskott-Aldrich syndrome
protein (WASp), which comprises 502 amino acids.
WASp is an important regulator of actin cytoskeletal rear-
rangements. Widely expressed in hematopoietic cells,
WASp is involved in various cellular functions including
cellular migration and immune synapse formation [5, 6].
Congenital thrombocytopenia and small platelets (mean
platelet volume of <5.0 fL in most patients) are the key
criteria in diagnosing WAS [7]. In this report, we describe
an unusual case of WAS in a Malay boy who presented
with early onset thrombocytopenia and a normal platelet
size.
Case presentation
A 9-month-old Malay boy was referred for further investi-
gations in view of persistent thrombocytopenia from birth.
He was admitted to the neonatal ward after birth due to
borderline prematurity at 35 weeks. A full blood count
taken on the first day of life (DOL 0) showed
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thrombocytopenia with a platelet count of 43,000/μL and
a normal mean platelet volume (MPV) of 8.4 fL. Results
from a TORCH screen (for Toxoplasma gondii, other vi-
ruses, rubella, cytomegalovirus, and herpes simplex) were
negative. He was treated for presumed sepsis. His platelet
count while on our ward ranged from 25,000/μL to
68,000/μL. After discharge, his platelet counts during
follow-up appointments at the clinic ranged from 20,000/
μL to 30,000/μL and no bleeding tendency was reported.
At the age of 3 months, our patient was admitted due to
bloody stools and petechiae (platelet count of 12,000/μL).
Following an intravenous infusion of immunoglobulin
(IVIG), his platelet count rose and he was discharged.
Unfortunately, in his subsequent admissions for epistaxis
and bloody stools, his platelet count did not improve even
after receiving IVIG. This observation and negative results
for an antiplatelet antibody assay raised suspicion for a
different underlying pathology and a blood sample was
collected from our patient forWAS gene analysis. Informed
consent for genetic testing was obtained from his parents
prior to molecular work. In addition, we also performed a
lymphocyte immunophenotyping assay and quantification
of his immunoglobulin levels.
Our patient was the only male among his siblings. His
parents were non-consanguineous. Two of his maternal
uncles died during infancy from unknown causes (at ages
1 month and 7 months). None of them was investigated
for WAS. A mutation analysis of our patient revealed a
c.1264G>T mutation in exon 10 of the WAS gene, which
led to a change in the 422nd amino acid from alanine to
serine. A sequence analysis of his mother showed that she
was a carrier. The sequence analysis is shown in Fig. 1.
Lymphocyte immunophenotyping showed elevated total
T lymphocytes of 3785 × 106/L (normal range for age
1700–3600 × 106/L), a CD8 count of 1621 × 106/L (normal
range for age 800–1200 × 106/L), a low CD4 count of
1356 × 106/L (normal range for age 1700–2800 × 106/L),
and normal concentrations of B lymphocyte and natural
killer cells. With regards immunoglobulin quantification,
he had elevated IgG (1149 mg/dL, normal range for age
400–900 mg/dL), IgA (268 mg/dL, normal range for age
20–60 mg/dL), IgM (126 mg/dL, normal range for age
35–75 mg/dL), and IgE (150 ku/L, normal range for age
2.6 ± 10 ku/L).
Our patient’s disease course deteriorated when he





G (wild type )
T (mutant)
Fig. 1 Chromatogram showing DNA sequence in healthy normal control, mother, and patient. There is a G>T mutation in the patient, resulting
in a change in the 422nd amino acid from alanine to serine
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severe episodes of hematemesis that required platelet and
packed-cell transfusion. Progressive hepatosplenomegaly
was also noted, raising suspicion for a malignant trans-
formation of WAS. Bone marrow aspiration was offered,
but his parents refused further treatment and then
defaulted on their follow-up appointments.
Discussion
In this report, we describe the case of a patient with WAS
who presented with incidental finding of thrombocytopenia
at birth. The unusual feature for this report is his normal
platelet size despite the thrombocytopenia, a characteristic
feature of WAS. There are very few reports describing
WAS cases with a normal platelet size. In a previously
published case report, Patel et al. describe the case of a boy
who presented with thrombocytopenia and normal platelet
size. Evaluation of WASp expression by flow cytometry
showed that he had reduced expression as compared to a
healthy control. Molecular analysis of the WAS gene
revealed a c.862A>T mutation in exon 9 [8]. In a more
recent case report, Mantadakis et al. described three cases:
a pair of twins with a c.854_855insA mutation in exon 9
and a patient with a c.743_743+1delAG mutation in exon
7. In all three cases, WASp expression was undetectable
[9]. Our patient demonstrated a novel mutation of
c.1264G>T in exon 10. A limitation of our report is the
absence of data on WASp expression.
The clinical manifestation of thrombocytopenia in WAS
is heterogeneous. In a study involving 154 patients with
WAS, the most common bleeding manifestation was either
petechiae or purpura, which was seen in 78 % of patients
[10]. Bleeding from the gastrointestinal tract, as seen in our
patient, only occurred in 28 % of the cases [10]. Splenec-
tomy and IVIG have been shown to improve platelet count
in WAS/XLT [11–13]. In our patient, IVIG alone was
inadequate to improve his platelet count. Splenectomy
could have been beneficial as a supportive treatment in our
case, but was not considered because our patient’s platelet
counts were persistently very low (<50,000/μL).
The WAS scoring system is used to categorize patients
according to disease severity [14]. A score of 1 indicates
that the patient has only thrombocytopenia, a score of 2
is given when the patient has thrombocytopenia with
additional findings of mild/transient eczema or minor
infections. Patients with a score of 1 and 2 are designated
as having XLT. Those with treatment-resistant eczema
and recurrent infections in spite of optimal treatment
receive a score of 3 (mild WAS) or 4 (severe WAS). A
score of 5 is given to patients with autoimmune disease or
malignancy, regardless of the original score. Using this
system, our patient had a score of 1, an indication of the
milder XLT variant.
Albert et al. investigated the clinical characteristics and
long-term outcome of 173 patients with XLT [15]. In their
study, there was no association between platelet count and
the risk of bleeding. Autoimmunity was seen in 12.1 % of
patients and malignancy in 6.9 %. This study suggested that
the score of each patient can change over time, and the
disease in a patient with XLT may evolve to a more severe
classical WAS phenotype. The possibility of malignant
transformation in our case could not be confirmed because
he was lost to follow-up.
The identification of a mutation in our patient and a
carrier state in his mother will enable family counseling in
any future pregnancies. An early diagnosis by means of
prenatal diagnosis or blood investigations taken in the first
few days of life in affected families will not only enable
early arrangement of stem cell transplantation, but also
avoid potential harmful procedures being administered to
infants with WAS, such as the administration of live
vaccines and intramuscular injections that may lead to
severe infection and bleeding tendencies.
Conclusions
WAS is a rare disorder with wide clinical manifestations.
In the mild WAS phenotype, which is classified as XLT,
this condition can be misdiagnosed as immune throm-
bocytopenic purpura, as seen in our patient. A diagnosis
of WAS should be considered in any male child with
congenital thrombocytopenia regardless of platelet size,
especially when there is a positive family history of early
death in male infants.
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